Charges are to be formally dropped in the case against former Sars employees in the so-called “rogue unit” case.
“The National Director of Public Prosecutions, Adv Shamila Batohi, has decided to withdraw charges against Ivan Pillay, Andries Janse Van Rensburg and Johan Van Loggerenberg. The NDPP has informed relevant prosecutors and the lawyers representing the accused of this decision,” said NPA spokesperson Bulelwa Makeke.
Pillay and Van Loggerenberg has also been charged with contravention of the Prevention and Combatting of Corrupt Activities Act. “Following the defence submitting representations to the NDPP in support of a request to have the decision to prosecute reviewed, the NDPP appointed a review panel to consider the matter, and to provide her with an opinion and recommendations ,” the statement read.“After a careful assessment of the evidence and other relevant material, the unanimous conclusion of the panel in respect of all counts, is that there are no reasonable prospects of a successful prosecution.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Sars mum about attachment of Trillian assetsEskom approached the court on January 17 seeking to have Trillian and its remaining director Eric Wood liquidated
Read more »
SARS recovers over R2-billion in taxesSARS is tackling the clothing and textile, leather, tobacco and fuel sectors.
Read more »
Sars mum about attachment of Trillian assetsEskom approached the court on January 17 seeking to have Trillian and its remaining director Eric Wood liquidated
Read more »
Nigerian court adjourns case of 47 men charged under homosexuality lawProsecution lawyer Ilyas Abdulrahman said their lead witness, the police inspector who led the raid in which the men were arrested, would appear on Wednesday.
Read more »
SARS recovers over R2-billion in taxesSARS is tackling the clothing and textile, leather, tobacco and fuel sectors.
Read more »
Merck spins off assets to focus on main growth drivers: cancer drugs, vaccinesWomen’s health unit, biosimilar drugs and other legacy products go into a separate publicly traded company
Read more »